The drug-drug interaction label for rosuvastatin drugs that are used to treat hyperlipidemia including AstraZeneca’s ‘Crestor’ will be changed.

The drugs that affect rosuvastatin are ticagrelor drugs including AstraZeneca’s antiplatelet drug ‘Brilinta.’ The labeling change for ticagrelor has been preannounced by the Ministry of Food and Drug Safety in August and is set to be made on December 2nd.

The labeling changes for rosuvastatin in line with the changes made for ticagrelor will also be applied after collecting opinions until December 2nd.

According to the planned changes that will be made, the phrase ‘Ticagrelor can cause renal insufficiency and may affect r